5.03
-1.37%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cronos Group
Its shares trade on Toronto Stock Exchange under the ticker CRON.TO. It has been listed since 7 May 2014. In the fiscal year to 31 December 2025, it reported revenue of $149.2m and a net loss of $9.6m. At that date it held total assets of $1.19bn and shareholders' equity of $1.09bn.
Cronos Group, Inc. engages in the production and distribution of cannabis. The company is headquartered in Toronto, Ontario. The company went IPO on 2014-05-07. The firm is focused on cannabis research, technology and product development. The Company’s portfolio includes PEACE NATURALS, COVE, Spinach, Lord Jones and PEACE+. PEACE NATURALS a global wellness platform. The COVE and Spinach are adult-use brands. The Lord Jones and PEACE+ are hemp-derived cannabidiol (CBD) brands. The Company’s segments include United States and Rest of World. The United States segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s subsidiaries include Cronos Israel G.S. Cultivations Ltd, Cronos Israel G.S. Manufacturing Ltd, Cronos Israel G.S. Store Ltd and Cronos Israel G.S. Pharmacies Ltd.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 May 2014
- Employees
- 665
- Website
- thecronosgroup.com ↗
Leadership
Pay as last reported
- Mr. Michael GorensteinExecutive Chairman of the Board, President, Chief Executive Officer, since 2016$4.2m
- Ms. Anna ShlimakChief Financial Officer, Senior Vice President$836,509
- Ms. Shannon BuggySenior Vice President, Global Head of People$760,580
- Mr. Adam WagnerSenior Vice President, Head of Cronos Israel
- Mr. Arye WeigensbergSenior Vice President, Head of Research & Development
- Mr. Jared KenostPrincipal Accounting Officer, Vice President, Controller
- Mr. Terry DoucetGeneral Counsel and Corporate Secretary, since 2022
- Mr. Jeffrey JacobsonChief Growth Officer$1.1m
- Mr. James RudykLead Independent Director$245,000
- Mr. Jason AdlerIndependent Director$215,000
- Mr. Murray GarnickIndependent Director$175,000
- Mr. Kamran KhanIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 30
- Environment
- 7
- Social
- 53
- Governance
- 30
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong brand reputation and market presence: Cronos Group Inc has established itself as a leading player in the cannabis industry, both in Canada and globally.
- Solid financial position: The company has sufficient financial resources, enabling it to invest in research and development, expand production capacities, and pursue strategic partnerships.
- Diverse product portfolio: Cronos Group offers a wide range of cannabis products, including dried flower, oils, and vaporizers, catering to different consumer preferences and market segments.
Weaknesses
- Regulatory challenges: The cannabis industry operates under strict regulations, which may result in uncertainties and constraints for Cronos Group, especially in international markets.
- Limited production capacity: Despite ongoing expansions, the company's production capacity may not be sufficient to meet the growing demand for cannabis products, potentially hindering market share growth.
- Higher product prices: Cronos Group's premium positioning and focus on quality may result in comparatively higher prices, making its products less affordable for price-sensitive consumers.
Opportunities
- Legalization and market expansion: Increasing legalization of cannabis across different jurisdictions presents opportunities for Cronos Group to penetrate new markets and drive sales growth.
- Expansion of product offerings: The company can diversify its product portfolio further by introducing innovative cannabis-based products, such as edibles, beverages, and cosmetics, to tap into evolving consumer trends.
- Strategic partnerships: Collaborating with established companies in related industries, such as pharmaceuticals or consumer goods, can provide Cronos Group with access to new distribution channels and enhance market reach.
Threats
- Competitive market landscape: The cannabis industry is becoming increasingly competitive, with the presence of both established players and new entrants, posing challenges for Cronos Group to maintain its market share and pricing power.
- Legal and regulatory risks: Changes in laws and regulations, both domestically and internationally, regarding the production, distribution, or use of cannabis can impact the company's operations and profitability.
- Negative social perception: Despite ongoing efforts to normalize the use of cannabis, societal stigma surrounding marijuana consumption may hinder widespread acceptance and limit the market potential for Cronos Group's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.